Oncology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Oncology Drugs Market
The oncology drugs market size was valued at USD 201.75 billion in 2023, and the market is now projected to grow from USD 220.80 billion in 2024 to USD 518.25 billion by 2032, exhibiting a CAGR of 11.3% during the forecast period of 2024-2032.
The global oncology pills enterprise skilled giant disruptions due to COVID-19, leading to deliver chain troubles and adjustments in bio-manufacturing. Pharmaceutical firms redirected R&D assets towards COVID-19 therapeutics and vaccines, ensuing in slower marketplace boom in 2020. Novartis AG's 2020 annual record mentioned an insignificant 2.4% increase inside the oncology tablets section as compared to the previous 12 months, exacerbated with the aid of biosimilar erosion.
The oncology drugs marketplace is poised for growth because of the escalating occurrence of most cancers international, rating most of the leading causes of loss of life throughout numerous nations. Factors such as tobacco smoking, expanded publicity to ultraviolet radiation, rising pollutants, and moving nutritional conduct contribute to the growing occurrence of cancer. As consistent with the Centers for Disease Control and Prevention (CDC), most cancers stand as the second leading reason of mortality inside the U.S., underscoring the urgent need for effective treatments and driving demand for oncology tablets.
The market is witnessing growth driven through a heightened attention on R&D aimed toward advancing drug treatment options for most cancers’ treatment. With a focus on curing the ailment, prolonging survival, and enhancing satisfactory of life, immunotherapy emerges as a promising strategy, leveraging immune cells' position in tumor progression. Leading gamers are heavily making an investment in immunotherapy studies to develop innovative remedies for more than a few cancers, driving market enlargement and adoption of superior remedies.
Comprehensive Analysis of Oncology Drugs Market
The oncology drugs market growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated by drug class analysis, by therapy analysis, by indication analysis, by dosage from analysis, by distribution channel analysis. By drug class analysis include, cytotoxic drugs, targeted drugs, hormonal drugs, and others. By therapy analysis include, chemotherapy, targeted therapy, and immunotherapy. By indication analysis include, lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and others. By dosage from analysis include, solid, liquid, and injectable. By distribution channel analysis include, hospital pharmacies, retail & online pharmacies.
The North America region lead the oncology drugs market share by benefitting a market size of USD 92.65 billion in 2023 due to growing incidence and rising prevalence of cancer in the U.S. and new product launches.
The top players within the marketplace play an important position inside the industry assuring marketplace increase and placing marketplace standards. These players include, F. Hoffmann-La Roche Ltd., Abbvie Inc., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, AstraZeneca, Sanofi, Bayer AG, Merck & Co., Inc these market players provide a level-playing competitive landscape.
In February 2024, AbbVie Inc. acquired ImmunoGen, a biotechnology company specializing in antibody-drug conjugate therapeutics for cancer treatment, to bolster its presence in the oncology sector.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 11.3% from 2024-2032
Unit Value (USD Billion)
Segmentation By Drug Class
Cytotoxic Drugs
Alkylating Agents
Antimetabolites
Others
Targeted Drugs
Monoclonal Antibodies
Others
Hormonal Drugs
Others
By Therapy
Chemotherapy
Targeted Therapy
Immunotherapy
By Indication
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Others
By Dosage Form
Solid
Tablets
Capsules
Liquid
Injectable
Prefilled Syringes
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America (By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- U.S. (By Drug Class)
- Canada (By Drug Class)
Europe (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- U.K. (By Drug Class)
- Germany (By Drug Class)
- France (By Drug Class)
- Italy (By Drug Class)
- Spain (By Drug Class)
- Scandinavia (By Drug Class)
- Rest of Europe (By Drug Class)
Asia Pacific (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- Japan (By Drug Class)
- China (By Drug Class)
- India (By Drug Class)
- Australia (By Drug Class)
- Southeast Asia (By Drug Class)
- Rest of Asia Pacific (By Drug Class)
Latin America (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- Brazil (By Drug Class)
- Mexico (By Drug Class)
- Rest of Latin America (By Drug Class)
Middle East & Africa (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
- South Africa (By Drug Class)
- GCC (By Drug Class)
- Rest of Middle East & Africa (By Drug Class)